May 2014

When Science Outpaces Payers: Reimbursement in Molecular Diagnostics

ByMary K. Caffrey

May 15th 2014

Everolimus in Elderly Hormone-Receptor-Positive Advanced Breast Cancer Patients

ByJaqueline Rogerio, MD

May 15th 2014

LETTER TO THE EDITOR.

The Role of Bioinformatics in Oncology Drug Development-and Precision Medicine

BySurabhi Dangi-Garimella, PhD

May 15th 2014

Choosing a BRCA Genetic Testing Laboratory: A Patient-Centric and Ethical Call to Action for Clinicians and Payers

ByEllen T. Matloff, MS, Rachel E. Barnett, MS,Robert Nussbaum, MD

May 15th 2014

Commentary

Mutations That Drive Lung Cancer Also Driving Frontiers of Treatment

ByMary K. Caffrey

May 15th 2014

NCCN Guidelines Updates

More Enthusiasm for Newer Melanoma Therapies

ByMary K. Caffrey

May 15th 2014

NCCN Guidelines Updates

Denlinger Discusses Posttreatment Surveillance for Cancer Survivors

ByMary K. Caffrey

May 15th 2014

NCCN Guidelines Updates

Promising News in Treating Multiple Myeloma

ByMary K. Caffrey

May 15th 2014

NCCN Guidelines Updates

Sorting Through Screening Protocols for Colorectal Cancer

ByMary K. Caffrey

May 15th 2014

NCCN guidelines Updates

Roche Molecular Diagnostic's cobas HPV Test Approved by the FDA

BySurabhi Dangi-Garimella, PhD

May 15th 2014

Protecting Bone Health During Cancer Care

ByMary K. Caffrey

May 15th 2014

NCCN Guidelines Updates

New NCCN Prostate Cancer Screening Guidelines Aim for Middle Ground

ByMary K. Caffrey

May 15th 2014

NCCN Guidelines Updates

The Big Data Revolution: From Drug Development to Better Health Outcomes?

ByAndrew Smith

May 15th 2014

Understanding Which Therapy Comes First in Treating Castration-Resistant Prostate Cancer

ByMary K. Caffrey

May 15th 2014

NCCN Guidelines Updates

CVS Caremark Quits for Good: Our Decision to Stop Selling Tobacco Products

ByTroyen A. Brennan, MD, MPH, Chief Medical Officer, CVS Caremark

May 15th 2014

NCCN Panel Asks What ACA Means to Cancer Care Delivery

ByMary K. Caffrey

May 15th 2014

NCCN Guidelines Updates

Stem Cells Create a Therapeutic Niche

BySurabhi Dangi-Garimella, PhD

May 15th 2014

Cheap and Easy-To-Use Diagnostic Tests to Detect Disease Biomarkers, Including Cancer

BySurabhi Dangi-Garimella, PhD

May 15th 2014

The Double Whammy of the Obesity Epidemic: Increased Susceptibility to Cancer

BySurabhi Dangi-Garimella, PhD

May 15th 2014

May 2014

When Science Outpaces Payers: Reimbursement in Molecular Diagnostics

Everolimus in Elderly Hormone-Receptor-Positive Advanced Breast Cancer Patients

The Role of Bioinformatics in Oncology Drug Development-and Precision Medicine

Choosing a BRCA Genetic Testing Laboratory: A Patient-Centric and Ethical Call to Action for Clinicians and Payers

Mutations That Drive Lung Cancer Also Driving Frontiers of Treatment

More Enthusiasm for Newer Melanoma Therapies

Denlinger Discusses Posttreatment Surveillance for Cancer Survivors

Promising News in Treating Multiple Myeloma

Sorting Through Screening Protocols for Colorectal Cancer

Roche Molecular Diagnostic's cobas HPV Test Approved by the FDA

Protecting Bone Health During Cancer Care

New NCCN Prostate Cancer Screening Guidelines Aim for Middle Ground

The Big Data Revolution: From Drug Development to Better Health Outcomes?

Understanding Which Therapy Comes First in Treating Castration-Resistant Prostate Cancer

CVS Caremark Quits for Good: Our Decision to Stop Selling Tobacco Products

NCCN Panel Asks What ACA Means to Cancer Care Delivery

Stem Cells Create a Therapeutic Niche

Cheap and Easy-To-Use Diagnostic Tests to Detect Disease Biomarkers, Including Cancer

The Double Whammy of the Obesity Epidemic: Increased Susceptibility to Cancer

Fast Track for Prima Biomed's CVac Clinical Trial Development Program

Trending on AJMC

Government Shutdown Concluded but ACA Subsidies in Limbo

Can a Coffee a Day Keep AFib Away?

FDA Approves Ziftomenib for R/R NPM1-Mutated AML

High BMI Drives Worldwide Surge in Ovarian, Uterine Cancer Cases

How MS Treatment Strategies Are Evolving: Rebecca Spain, MD